Dataset Information

Lessons about Virtual-Environment Software Systems from 20 years of VE building.

ABSTRACT: What are desirable and undesirable features of virtual-environment (VE) software architectures? What should be present (and absent) from such systems if they are to be optimally useful? How should they be structured? To help answer these questions we present experience from application designers, toolkit designers, and VE system architects along with examples of useful features from existing systems. Topics are organized under the major headings of: 3D space management, supporting display hardware, interaction, event management, time management, computation, portability, and the observation that less can be better. Lessons learned are presented as discussion of the issues, field experiences, nuggets of knowledge, and case studies.

SUBMITTER: Taylor RM

PROVIDER: S-EPMC2887604 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Lessons about Virtual-Environment Software Systems from 20 years of VE building.

Taylor Russell M RM Jerald Jason J Vanderknyff Chris C Wendt Jeremy J Borland David D Marshburn David D Sherman William R WR Whitton Mary C MC

Presence (Cambridge, Mass.) 20100401 2

What are desirable and undesirable features of virtual-environment (VE) software architectures? What should be present (and absent) from such systems if they are to be optimally useful? How should they be structured? To help answer these questions we present experience from application designers, toolkit designers, and VE system architects along with examples of useful features from existing systems. Topics are organized under the major headings of: 3D space management, supporting display hardwa ...[more]

PMID: 20567602

Similar Datasets

Project description:Identifying opportunities and limitations for closing yield gaps is essential for setting right the efforts dedicated to improve germplasm and agronomic practices. This study analyses genotypes × environments interaction (G × E), genetic progress, and grain yield stability under contrasting production systems. For this, we analyzed datasets obtained from three Swiss trial-networks of winter wheat that were designed to evaluate genotypes under organic farming conditions, conventional management with low-inputs (150 kg nitrogen (N) ha-1 with no fungicide application) and conventional management with high-inputs (170 kg N ha-1 with fungicide application). The datasets covered the periods from 1998 to 2018 for organic and conventional management with low-inputs and from 2008 to 2018 for conventional management with high-inputs. The trial-networks evaluated each year an average of 36 winter wheat genotypes that included released varieties, advanced breeding lines, and lines for registration and post-registration in Switzerland. We investigated within each trial-network the influence of years, genotypes, environments and their interactions on the total variance in grain yield and grain N concentration using variance components analyses. We further applied mixed models with regression features to dissect genetic components due to breeding efforts from non-genetic components. The genotype as a single factor or as a factor interacting with the environment or the year (G × E, G × year, and G × E × year) explained 13% (organic), 20% (conventional low-inputs), and 24% (conventional high-inputs) of the variance in grain yield, while the corresponding values for grain N concentration were 29%, 25%, and 32%. Grain yield has stagnated since 1990 for conventional systems while the trend under organic management was slightly negative. The dissection of a genetic component from the grain yield trends under conventional management showed that genetic improvements contributed with 0.58 and 0.68 t ha-1 y-1 with low- and high- inputs, respectively. In contrast, a significant genetic source in the grain yield trend under organic management was not detected. Therefore, breeding efforts have been less effective on the wheat productivity for organic farming conditions than for conventional ones.

Project description:BackgroundCanada was one of the first countries to regulate the medical use of cannabis. However, literature on Canada's medical cannabis program is limited.MethodsWe use administrative data from the medical cannabis program, and licensed cannabis vendor catalog data to describe a) the participation of patients, physicians, and cannabis vendors in the program from its inception in 1999 to 2021, and b) trends in medical cannabis consumption, prices and potency. We also use national surveys conducted over the last several decades to estimate trends in regular cannabis use (medical or otherwise) and how it changed during the medical cannabis access regimes.ResultsIn 2001, the Canadian government granted access to those with physician-documented evidence of a severe health problem that could not be managed using conventional therapies. Most patients accessed cannabis grown under a personal production license. By 2013, authorized daily cannabis dosages were very high. In 2014, the government, concerned over illegal diversion, required that cannabis be purchased from a licensed commercial grower; personal production was banned. Physicians were given responsibility for authorizing patient access. To fill the regulatory void, the physician regulatory bodies in Canada imposed their own prescribing restrictions. After these changes, the number of physicians who were willing to support patient cannabis use markedly decline but the number of patients participating in the program sharply increased. Medical cannabis use varied by province-rates were generally lower in provinces with stricter regulations on physician cannabis prescribing. Most varieties of cannabis oil available for sale are now high in CBD and low in THC. Dry cannabis varieties, conversely, tend to be high in THC and low in CBD. Inflation adjusted prices of most varieties of medical cannabis have declined over time. We find that rates of daily cannabis use (medical or otherwise) increased markedly after the 2014 policy regime. The fraction of Canadians using cannabis daily increased again after the 2018 legalization of recreational cannabis; at the same time, participation in the medical access program declined.ConclusionThe implications for patient health outcomes of changes in the medical cannabis program and legalization of recreational use remains an important area for future research.

Project description:ObjectiveDespite a multitude of detection and treatment advances in the past 2 decades, prostate cancer remains the second leading cause of deaths due to cancer among men in the United States. Technological evolution and expanding knowledge of tumor biomarkers have invigorated exploration in prostate cancer therapeutics. Prostate-specific membrane antigen (PSMA) was one of the first prostate cancer biomarkers successfully cloned. Since then, it has been characterized as the prototypical cell-surface marker for prostate cancer and has been the subject of intense clinical inquiry. In this article, we review the relevant research in PSMA on the 20th anniversary of its cloning.Methods and materialsA PubMed search using the keywords "prostate-specific membrane antigen" or "glutamate carboxypeptidase II" provided 1019 results. An additional 3 abstracts were included from scientific meetings. Articles were vetted by title and abstract with emphasis placed on those with clinically relevant findings.ResultsSixty articles were selected for inclusion. PSMA was discovered and cloned in 1993. Its structure and function were further delineated in the ensuing decade. Consensus sites of expression in normal physiology are prostate, kidney, nervous system, and small intestine. PSMA has been implicated in the neovasculature of several tumors including urothelial and renal cell carcinomas. In prostate cancer, expression of PSMA is directly related to the Gleason grade. PSMA has been tested both in imaging and therapeutics in a number of prostate cancer clinical trials. Several recent approaches to target PSMA include the use of small molecule inhibitors, PSMA-based immunotherapy, RNA aptamer conjugates, and PSMA-targeted prodrug therapy. Future study of PSMA in prostate cancer might focus on its intracellular functions and possible role in tumor neurogenesis.ConclusionsTwenty years from its discovery, PSMA represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging.

Dataset Information

Lessons about Virtual-Environment Software Systems from 20 years of VE building.

Publications

Lessons about Virtual-Environment Software Systems from 20 years of VE building.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets